Search

Your search keyword '"Jarvie EM"' showing total 1 results
Start Over Author "Jarvie EM" Publisher american chemical society

Refine your results

1 results on '"Jarvie EM"'

1. Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate.

Author

Westaway SM, Brown SL, Fell SC, Johnson CN, MacPherson DT, Mitchell DJ, Myatt JW, Stanway SJ, Seal JT, Stemp G, Thompson M, Lawless K, McKay F, Muir AI, Barford JM, Cluff C, Mahmood SR, Matthews KL, Mohamed S, Smith B, Stevens AJ, Bolton VJ, Jarvie EM, and Sanger GJ

Subjects
Animals, Dogs, Gastrointestinal Motility drug effects, Humans, Muscle Contraction drug effects, Piperazines chemistry, Piperidines chemistry, Pyloric Antrum physiology, Rabbits, Rats, Drug Discovery, Gastrointestinal Agents pharmacology, Piperazines pharmacology, Piperidines pharmacology, Pyloric Antrum drug effects, Receptors, Gastrointestinal Hormone agonists, Receptors, Neuropeptide agonists
Abstract

N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist activity results in potentiation of the amplitude of neuronal-mediated contractions of isolated gastric antrum tissue. Compound 12 also possesses highly promising pharmacokinetic profiles in both rat and dog, and these results, in combination with further profiling in human native tissue and an in vivo model of gastrointestinal transit in the rabbit, have led to its selection as a candidate for further development.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results